🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Health insurer Centene confident about improving costs next year

Published 07/26/2024, 12:19 PM
Updated 07/26/2024, 12:21 PM
© Reuters. U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration
CNC
-

By Sriparna Roy and Amina Niasse

(Reuters) -Centene Corp said on Friday it expects medical costs to improve next year as states catch up with reassessment of enrollments for its Medicaid plans that cover lower-income people, lifting its shares about 9%.

The health insurer did not provide a forecast for 2025, but said it expects its Medicaid business to return to the pre-pandemic range.

Costs have surged for insurers after states began reassessing Medicaid enrollment eligibility following the termination of a policy last year that required insurers to keep low-income Americans enrolled through the COVID-19 pandemic.

The reassessment had led to an increase in the number of sicker patients in insurers' Medicaid membership profile and a fall in memberships.

Though Centene (NYSE:CNC) still expects medical care use to remain higher than initially expected in the second half of 2024, an improvement in membership could help alleviate some cost pressures on the company.

The company is confident that the mismatch between its expenses on Medicaid members and what states are paying the insurer to treat those members, is a "temporary fixable dynamic," said CEO Sarah London.

Centene also expects robust growth in its commercial health plans. It increased its 2024 premium and service revenue forecast by $5 billion to be between $141 billion and $143 billion.

However, it forecast annual medical loss ratio - a metric that tracks medical costs - to be at the higher end of its previous range of 87.3% and 87.9%. Analysts' were expecting a lower number, at 87.8%.

"We prefer to take a wait-and-see approach" through the second half of the year to see how the trends continue to develop, said Mizuho analyst Ann Hynes.

Centene expects to provide a detailed 2025 outlook in December.

© Reuters. U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration

Its second-quarter medical loss ratio rose to 87.6% from 87% a year earlier. Analysts had expected 86.84%.

Adjusted profit of $2.42 per share beat estimates of $2.07.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.